Launched in 2019, Dewpoint is based on the work of Anthony Hyman, a researcher who was part of the team that discovered biomolecular condensates. Shape-shifting blobs, these condensates form inside cells and can contain proteins and other molecules. Researchers have started to explore how condensates affect chemical reactions in the cell and potentially play a role in disease.
Dewpoint is one of several biotechnology companies attempting to create new treatments through studying condensates. While Dewpoint is working across several different therapeutic areas, its metabolic research is what drew the attention of Novo, the pharma company that sells the in-demand diabetes drug Ozempic.
The partnership will focus on the discovery of small molecule drugs to treat insulin resistance and diabetic complications. The companies claim that undoing the dysregulation of condensates could help forestall development of insulin resistance, which is a key factor in Type 2 diabetes. READ MORE
by Delilah Alvarado
Source: biopharmadive.com
In 2017, Sanofi partnered with the Lebanon, New Hampshire-based ImmuNext to develop an antibody for autoimmune diseases like lupus and multiple sclerosis, which included giving Sanofi a worldwide license to develop frexalimab. The agreement involved milestone payments upto $500 million.
Global manufacturer for the pharmaceutical, biotech and nutraceutical markets, Lonza has announced that it has acquired Synaffix, a biotech company focused on the commercialisation of its clinical stage technology platform for the development of antibody-drug conjugates (ADCs).
In its hunt for the new head of its pharmaceutical systems business—which makes syringes, self-injection systems and other drug delivery devices for 70% of the top 100 drugmakers in the world, according to the company—BD landed on a candidate with plenty of experience among that customer group.
